Patients with type 2 diabetes who switched from DPP-4 inhibitors to oral semaglutide experienced significantly lower oxidative stress and more stable blood sugar levels over 24 weeks.
Significant reduction in oxidative stressSwitching to oral semaglutide reduced oxidative stress markers significantly compared to continuing DPP-4 inhibitors — a finding that goes beyond standard blood sugar measures.
What the researchers found
Switching from DPP-4 inhibitors to oral semaglutide for 24 weeks significantly reduced oxidative stress (measured by the diacron-reactive oxygen metabolites test), improved glucose variability as measured by continuous glucose monitoring, and lowered HbA1c levels compared to continuing DPP-4 inhibitor therapy.
Importantly, while the metabolic and biochemical markers improved significantly, patient-reported treatment satisfaction scores did not differ between groups, indicating the benefits were measurable but didn't translate to a perceived difference in quality of life over this time period.
Why it matters
As GLP-1 receptor agonists like semaglutide become increasingly available in oral form, clinicians need evidence to guide decisions about switching patients from older diabetes medications. This study provides direct comparative data showing that the switch offers measurable metabolic benefits beyond just blood sugar control — including reduced oxidative stress, which is linked to long-term cardiovascular complications.
How the study worked
This was an open-label, prospective, randomized, multicenter, parallel-group study over 24 weeks. 58 patients with type 2 diabetes who had been on DPP-4 inhibitors for at least 12 weeks were randomized to either continue their DPP-4 inhibitor (n=28) or switch to oral semaglutide starting at 3 mg/day, increased to 7 mg/day after 4 weeks (n=30). Glucose variability was measured using continuous glucose monitoring. Final analysis included 51 patients (24 semaglutide, 27 DPP-4).
Who was studied
Adults with type 2 diabetes previously on DPP-4 inhibitors
What this study cannot tell us
The open-label design means neither patients nor doctors were blinded to treatment assignment, which could introduce bias. The sample size was small (58 enrolled, 51 analyzed), and 7 patients dropped out — 6 from the semaglutide group. The 24-week duration may not capture long-term outcomes. The study did not report specific effect sizes for oxidative stress or glucose variability in the abstract.
How to read the evidence
This is a prospective, randomized, multicenter comparative study, which provides moderate-to-strong clinical evidence. However, the open-label design and small sample size are notable limitations.
When this study was published
Published in 2025, this is very recent research reflecting the latest clinical experience with oral semaglutide in real-world diabetes management.
The bigger picture
Oral semaglutide represents a major shift in GLP-1 peptide therapy — previously only available as injections. This study adds to evidence that oral semaglutide may offer advantages beyond glycemic control, specifically in reducing oxidative stress that contributes to diabetic complications. As the GLP-1 agonist class continues to expand, head-to-head comparisons like this help define where these peptide-based therapies fit in treatment algorithms.
Questions still open
- Does the reduction in oxidative stress from semaglutide translate to fewer cardiovascular events over the long term?
- Would higher semaglutide doses (14 mg) produce even greater improvements in oxidative stress and glucose variability?
- Why did 6 patients drop out of the semaglutide group — were gastrointestinal side effects a factor?
Common questions
What is the advantage of oral semaglutide over DPP-4 inhibitors?
Why does reducing oxidative stress matter in diabetes?
Read the original research
Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study.
Diabetology & metabolic syndrome, 17(1), 126
Citation
Ohara, Makoto; Yokoyama, Hiroki; Seino, Hiroaki; Fujikawa, Tomoki; Kohata, Yo; Takahashi, Noriyuki; Irie, Shunichiro; Terasaki, Michishige; Mori, Yusaku; Fukui, Tomoyasu; Yamagishi, Sho-Ichi. (2025). Effects of switching from dipeptidyl peptidase 4 inhibitors to oral semaglutide on oxidative stress and glycemic variability in patients with type 2 diabetes: an open-label, prospective, randomized, multicenter, parallel-group comparison study.. Diabetology & metabolic syndrome, 17(1), 126. https://doi.org/10.1186/s13098-025-01691-y